Antagonists of the P2X(7) receptor. From lead identification to drug development.
Guile
Simon D
SD
Department of Medicinal Chemistry, AstraZeneca R&D Charnwood, Bakewell Road, Loughborough, LE11 5RH, UK. simon.guile@astrazeneca.com
Alcaraz
Lilian
L
Birkinshaw
Timothy N
TN
Bowers
Keith C
KC
Ebden
Mark R
MR
Furber
Mark
M
Stocks
Michael J
MJ
D000577:Amides / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use; D000578:Amidines / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use; D000818:Animals; D001172:Arthritis, Rheumatoid / Q000188:drug therapy; D001393:Azoles / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use; D055808:Drug Discovery; D006801:Humans; D058919:Purinergic P2 Receptor Antagonists; D058486:Receptors, Purinergic P2X7; D013329:Structure-Activity Relationship
D000577:Amides; D000578:Amidines; D001393:Azoles; C546468:P2RX7 protein, human; D058919:Purinergic P2 Receptor Antagonists; D058486:Receptors, Purinergic P2X7